Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticonvulsants in pregnancy.

C J Kilpatrick1, R F Moulds

  • 1Royal Melbourne Hospital, Parkville, Vic.

The Medical Journal of Australia
|February 4, 1991
PubMed
Summary

Anticonvulsant drug levels decrease during pregnancy, necessitating regular monitoring. Using a single drug at the lowest effective dose minimizes risks like birth defects and oral contraceptive failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal deformation mapping in MRI negative PET positive temporal lobe epilepsy.

Journal of neurology, neurosurgery, and psychiatry·2007
Same author

Contrast-enhanced perfusion and diffusion MRI accurately lateralize temporal lobe epilepsy: a pilot study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2007
Same author

"Magnetic resonance imaging negative positron emission tomography positive" temporal lobe epilepsy: FDG-PET pattern differs from mesial temporal lobe epilepsy.

Molecular imaging and biology·2006
Same author

MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome.

Brain : a journal of neurology·2004
Same author

Amygdala volumetry in "imaging-negative" temporal lobe epilepsy.

Journal of neurology, neurosurgery, and psychiatry·2003
Same author

Onset seizures independently predict poor outcome after subarachnoid hemorrhage.

Neurology·2000

Area of Science:

  • Pharmacology
  • Obstetrics
  • Neurology

Background:

  • Anticonvulsant drugs are commonly prescribed for epilepsy and other conditions.
  • Pregnancy significantly alters drug pharmacokinetics, posing challenges for managing maternal and fetal health.
  • Understanding these changes is crucial for optimizing treatment and minimizing adverse outcomes.

Purpose of the Study:

  • To review potential problems associated with anticonvulsant use during pregnancy.
  • To outline management strategies for these challenges.
  • To assess the impact on pharmacokinetics, teratogenicity, breastfeeding, and oral contraceptive efficacy.

Main Methods:

  • Literature review of studies published between 1968 and 1990.
  • Focused on anticonvulsant pharmacokinetics in pregnancy.
Keywords:
AustraliaBiologyBreast FeedingContraceptionContraceptive MethodsDeveloped CountriesDrugs--administraction and dosageDrugs--pharmacodynamicsFamily PlanningHealthHuman MilkInfant NutritionLactationMaternal PhysiologyNeurologic EffectsNutritionOceaniaOral ContraceptivesPhysiologyPregnancyReproductionRisk FactorsTreatment

Related Experiment Videos

  • Examined teratogenicity, breastfeeding, and oral contraceptive interactions.

    • Main Results:

    • Plasma anticonvulsant levels generally decrease during pregnancy due to factors like altered absorption, distribution, and clearance.
    • All anticonvulsants carry teratogenic risks, with higher risks associated with multiple drugs and higher doses.
    • Anticonvulsants are excreted in low levels in breast milk; most interact with oral contraceptives via liver enzyme induction, except valproic acid.

    Conclusions:

    • Regular monitoring of anticonvulsant plasma concentrations is essential during pregnancy.
    • Adjusting dosage based solely on total plasma levels may be misleading due to altered protein binding.
    • Minimizing teratogenicity involves using a single anticonvulsant at the lowest effective dose; breastfeeding is generally considered safe.